Observational studyDrug safety2021

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.

Veena Hoffman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.